Podcasts about celularity

In this episode, Bob and Peter discuss Stem Cells 101, why it's not available in America, and the importance of stem cell treatment for humanity.  Recorded on Nov 21st, 2024 Views are my own thoughts; not Financial, Medical, or Legal Advice. Dr. Robert Hariri is the Chairman, Founder, and CEO of Celularity, Inc., a leader in human cellular therapeutics developing placental stem cell-based therapies for cancer, autoimmune diseases, and other conditions. A distinguished surgeon, scientist, and entrepreneur, Dr. Hariri is known for discovering pluripotent stem cells from the human placenta and holds over 170 patents in the field. He founded Anthogenesis Corporation, later acquired by Celgene, and co-founded Human Longevity, Inc. Dr. Hariri, an MD and PhD graduate from Cornell University, serves as an Adjunct Professor of Neurosurgery at Weill Cornell Medical College and has earned prestigious honors, including the Pontifical Medal for Innovation and two Thomas Alva Edison Awards. His groundbreaking work continues to shape regenerative medicine and immuno-oncology. He's also a founding partner of Fountain Life. Learn more about Celularity: https://celularity.com/  Lifebank USA: https://www.lifebankusa.com/  Get my Longevity Guidebook here: https://qr.diamandis.com/book-audiopodcast ____________ I only endorse products and services I personally use. To see what they are, please support this podcast by checking out our sponsors:  Get started with Fountain Life and become the CEO of your health: https://fountainlife.com/peter/ AI-powered precision diagnosis you NEED for a healthy gut: https://www.viome.com/peter  Get 15% off OneSkin with the code PETER at  https://www.oneskin.co/ #oneskinpod _____________ I send weekly emails with the latest insights and trends on today's and tomorrow's exponential technologies. Stay ahead of the curve, and sign up now: Tech Blog _____________ Connect With Peter: Twitter Instagram Youtube Moonshots

Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairperson, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies.Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri has served on numerous public boards including Cryoport. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). Dr. Hariri and his team of scientists were the first to obtain FDA approval to use its cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy to treat COVID-19 infected adults. He holds over 170 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.

In this episode featuring entrepreneur & author Peter Diamandis, we discuss: Why Peter Diamandis emphasizes the importance of having a mission and passion in life How mindset plays a crucial role in longevity and success How living in a Bitcoin world can provide financial security for the future (when we're living to be 100+ years old) Why the next decade will see more progress than the last century. Optimism about the future being essential for personal growth and success. How AI will democratize education and healthcare Privacy being increasingly compromised in the digital age What the world will look like by 2050 ---- Bio: Named by Fortune as one of the “World's 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is co-founder of BOLD Capital Partners, a venture fund with $500M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Follow him on X: https://x.com/PeterDiamandis  ---- Coin Stories is powered by Bitdeer Technologies Group (NASDAQ: BTDR), a publicly-traded leader in Bitcoin mining that stands alone as the only vertically-integrated, technology-focused Bitcoin mining company. Learn more at www.bitdeer.com.  ---- Natalie's Promotional Links:  Secure your Bitcoin with collaborative custody and set up your inheritance plan with Casa:  https://www.casa.io/natalie   For easy, low-cost, instant Bitcoin payments, I use Speed Lightning Wallet. Get 5000 sats when you download using this link and promo code COINSTORIES10: https://www.speed.app/sweepstakes-promocode/ River is where I DCA weekly and buy Bitcoin with the lowest fees in the industry: https://partner.river.com/natalie  Safely self-custody your Bitcoin with Coinkite and the ColdCard Wallet. Get 5% off: https://store.coinkite.com/promo/COINSTORIES Master your Bitcoin self-custody with 1-on-1 help and gain peace of mind with the help of The Bitcoin Way: https://www.thebitcoinway.com/natalie Bitcoin 2025 is heading to Las Vegas May 27-29th! Join me for my 4th Annual Women of Bitcoin Brunch! Get 10% off Early Bird passes using the code HODL: https://tickets.b.tc/affiliate/hodl/event/bitcoin-2025   Protect yourself from SIM Swaps that can hack your accounts and steal your Bitcoin. Join America's most secure mobile service, trusted by CEOs, VIPs and top corporations: https://www.efani.com/natalie  Connect with Bitcoiners and Bitcoin merchants wherever you live and travel on the Orange Pill App: https://signup.theorangepillapp.com/opa/natbrunell ---- This podcast is for educational purposes and should not be construed as official investment advice. ---- VALUE FOR VALUE — SUPPORT NATALIE'S SHOWS Strike ID https://strike.me/coinstoriesnat/ Cash App $CoinStories   #money #Bitcoin #investing

Welcome to the Green Rush, a weekly conversation at the intersection of cannabis, psychedelics, the capital markets, and culture, produced by KCSA Podcast Labs. Today, we have a special episode featuring our newest production, Alternatively Speaking. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare. We sat down with Dr. Bob Harari, a renowned biomedical scientist, surgeon, and entrepreneur. He is the Founder, Chairman, and CEO of Celularity, a biotechnology company leading the next evolution in cellular medicine. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration.  Dr. Hariri is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Podcast Highlights: Introduction & Dr. Bob Harari's Research (1:00): Dr. Harari's background and journey to longevity science. Placental Stem Cells (04:30): Advantages of using placental-derived stem cells and their ethical considerations. Universal Donor Tissue (10:05): Concept of the placenta as a universal donor tissue is explored, highlighting its potential in cellular therapies. Genetic Modification (12:40): Process of genetic modification in stem cells and their natural intelligence. Chimerism (20:35): The potential therapeutic benefits of chimerism in cellular medicine are discussed. Adult Stem Cell Banking (24:18): Cellularity's adult stem cell banking program and its value for future treatments. Future of Stem Cell Medicine (36:40): A vision of stem cell medicine in 10 years, including potential treatments for cancer, autoimmune diseases, and aging-related conditions. Social Media: Dr. Bob Hariri's Instagram: https://www.instagram.com/drbobhariri/?hl=en  Dr. Bob Hariri's LinkedIn: https://www.linkedin.com/in/bob-hariri-md-phd-3654b239/  Other Links/Mentions/Resources: Cellularity's official website: https://www.cellularity.com/  National Institutes of Health (NIH) information on stem cells: https://stemcells.nih.gov/  FDA resources: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products  Nature article on chimerism: https://www.nature.com/articles/d41586-021-01001-2  The American Society for Gene and Cell Therapy's patient education page: https://asgct.org/education  Show Credits: This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.  Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas. You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels: X: @KCSAPodcastLabs Instagram: @KCSAPodcastLabs LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/

Last week, I talked about the four pillars of healthy aging.  Last on the list - but definitely not least - was youthful aesthetics. Stem cells can have a tremendous impact on the health of our skin.  We're seeing it with regard to the treatment of burns. In fact, my company, Celularity, has a product that utilizes stem cells for the treatment of burns.  We're also seeing more and more skin care companies use stem cells for everyday products and therapies. The health of our skin - the body's largest organ - is an important part of our overall health and our lifespan. In this episode, I'll look at how stem cells can be used to heal skin damage and help us maintain our youthful aesthetics.Follow Dr. Bob Hariri on his platforms here:Web: www.pilotinghealth.comInstagram: https://www.instagram.com/drbobhariri/X: https://twitter.com/DrBobHaririTikTok: https://www.tiktok.com/@pilotinghealthLinkedIn: https://www.linkedin.com/in/drbobhariri/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/NAX865. CME/MOC/AAPA credit will be available until December 16, 2024.Shattering the Barriers to Glioblastoma Care: Revolutionary Advances With Innovative Technologies and Modern Systemic Approaches In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Blue Earth Diagnostics and Novocure, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSteven Brem, MD, has no financial interests/relationships or affiliations in relation to this activity.Faculty/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Grant/Research Support from Seagen Inc.Stock Shareholder in CytoDyn Inc.; MedInnovate Advisors LLC; and MimiVax, LLC.Faculty/PlannerMichelle Kim, MD, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Blue Earth Diagnostics.Patient/PlannerJB Bird has no financial interests/relationships or affiliations in relation to this activity.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/AWE865. CME credit will be available until December 27, 2024.Brainstorming New Approaches to Improve Glioblastoma Care: Revolutionary Advances With Modern Gene Fusion–Targeted Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerManmeet S. Ahluwalia, MD, MBA, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; Apollomics, Inc.; Autem Therapeutics; Bayer Corporation; Bugworks; Cairn Therapeutics; Caris Life Sciences; Celularity, Inc.; GSK; GT Medical Technologies; Insightec; Janssen Pharmaceuticals, Inc.; Kiyatec Inc.; Modifi Bio; NH TherAguix; Novocure, Inc.; Nuvation Bio, Inc.; Prelude Therapeutics; Pyramid Biosciences; Sumitomo Dainippon Pharma Oncology; The Menarini Group; Tocagen Inc.; Varian Medical Systems, Inc.; ViewRay Technologies, Inc.; Voyager Therapeutics, Inc.; and Xoft, a subsidiary of iCAD, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

View the Show Notes For This Episode And Links To Full Length Episodes Featured In This CompilationGet Free Weekly Health Tips from Dr. HymanSign Up for Dr. Hyman's Weekly Longevity JournalGet Ad-free Episodes & Dr. Hyman+ Audio ExclusivesIn today's episode, I talk with Dr. Scott Sherr, Dr. Bob Hariri, and Ben Greenfield about why hyperbaric oxygen is a great choice for brain health conditions and how stem cell therapy helps with chronic pain relief, reduces inflammation, and increases energy. We also discuss sauna and red light therapy.Dr. Scott Sherr is a Board Certified Internal Medicine Physician Certified in Hyperbaric Oxygen Therapy and Health Optimization Medicine (HOMe). He is the founder of Integrative HBOT, a worldwide telemedicine practice where he consults and educates patients and clinics using his novel approach to hyperbaric therapy that includes cutting-edge and dynamic HBOT protocols, comprehensive laboratory testing (using the HOMe framework), targeted supplementation, personal practices, synergistic technologies (new and ancient), and more. Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine, and aerospace. He is the chairperson, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases. Ben Greenfield is a human performance consultant, speaker, and New York Times bestselling author of 13 books, including the wildly popular titles, Beyond Training and Boundless. Ben hosts the highly popular fitness, nutrition, and wellness website BenGreenfieldFitness.com, a site with over a million monthly visitors, featuring articles, podcasts, and product reviews.This episode is brought to you by Rupa Health, Paleovalley, and FOND.Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com.Paleovalley is giving listeners an additional 15% off their first order. Just visit Paleovalley.com/Hyman to save on clean snacks and supplements.Get FOND's amazing bone broth today. Just go to FondBoneBroth.com/DrHyman and use code HYMAN20 to get 20% off your purchase.Connect with Dr. Mark Hyman on Twitter, Instagram, Facebook, and YouTube Hosted on Acast. See acast.com/privacy for more information.

Recently named by Fortune as one of the “World's 50 Greatest Leaders,” Peter Diamandis is the Founder and Executive Chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the Executive Founder of Singularity University. As an entrepreneur, Diamandis has started over 25 companies in the areas of health tech, space, venture capital, and education. He is the Co-founder and Vice-Chairman of two public companies, Celularity and Vaxxinity. Dr. Diamandis is Co-founder & Chairman of Fountain Life, a fully-integrated platform delivering predictive, preventative, personalized, and data-driven health. Finally, he also serves as Co-founder of BOLD Capital Partners, a venture fund with half-billion dollars under management being invested in exponential technologies and longevity companies. Diamandis is a New York Times Bestselling author of four books: Abundance – The Future Is Better Than You Think, BOLD – How to Go Big, Create Wealth & Impact the World, and The Future is Faster Than You Think. Most recently, he co-authored the #1 best seller LIFE FORCE with Tony Robbins, which chronicles the extraordinary healthcare and biotech revolution unfolding before our eyes. He earned degrees in molecular genetics and aerospace engineering from MIT and holds an M.D. from Harvard Medical School. Diamandis' favorite saying is, “The best way to predict the future is to create it yourself.”Buy his new books, Longevity and Exponential Organizations 2.0In this episode you will learnInsights into the current state of research and technology in extending human lifespan, and what the future holds.How to prepare your body and mind for achieving audacious goals, embracing the concept of 'moonshot thinking'.How individuals and organizations can develop a mindset that encourages risk-taking and boundary-pushing for innovative success.About the most recent breakthroughs and advancements in life extension and why they are promising.The major challenges and obstacles that researchers face in the quest to extend human lifespan.For more information go to www.lewishowes.com/1541For more Greatness text PODCAST to +1 (614) 350-3960More SOG episodes we think you'll love:Rob Dial – https://link.chtbl.com/1516-podDr Joe Dispenza – https://link.chtbl.com/1494-podInky Johnson – https://link.chtbl.com/1483-pod

Peter Diamandis.  A.I. WILL DISRUPT EVERYTHING, 10X GROWTH & CREATE MASSIVE WEALTH 5,091 views • July 21, 2023 Listen to the podcast https://londonreal.tv/peter-diamandis-a-i-will-disrupt-everything-10x-growth-create-massive-wealth/#popup1 Listen to the first 24 minutes on Rumble- https://rumble.com/v31khe1-early-access-peter-diamandis-a.i.-will-disrupt-everything-10x-growth-and-cr.html Serial Entrepreneur & Business Leader Get The Book I'm delighted to be joined today by Peter Diamandis, a serial entrepreneur, business leader, author, world-renowned speaker and philanthropist to get a better understanding of exactly what is happening in the world of technology innovation and artificial intelligence. Peter has had a long and storied career, starting over 20 companies in the areas of longevity, space, venture capital and education since he graduated MIT in the early ‘80s and subsequently completing his Doctor of Medicine studies at Harvard Medical School. Peter's entrepreneurial spirit, fascination with space travel and thirst to innovate are central to his core business philosophy and approach of “exponential thinking”. He advocates that technology and innovation progress exponentially and that disruptive technologies and entrepreneurial approaches can solve humanity's most significant challenges and create a future of abundance. Peter is focused on the idea of leveraging technology and market forces to drive positive change and encourages individuals, business owners and budding entrepreneurs to think big, take risks, and embrace failure as an essential part of the learning process. In the mid ‘90s, Peter founded the XPRIZE Foundation, a non-profit organisation with the goal of bringing about radical breakthroughs for the benefit of humanity through incentivised competitions. The foundation gained global attention with its first competition, the Ansari XPRIZE, which resulted in the flight of SpaceShipOne in 2004, firmly establishing the viability of private space travel. In 2008, Peter co-founded the Singularity University, a benefit corporation that aims to educate, inspire and empower leaders to apply exponential technologies to address humanity's grand challenges. Peter also oversees Human Longevity Inc., Futureloop, Bold Capital Partners and Celularity among many others, in a diverse and wide ranging portfolio of businesses. As an author, Peter has teamed up with former London Real guest Steven Kotler to write the bestsellers “Abundance: The Future Is Better Than You Think“, “Bold: How to Go Big, Create Wealth, and Impact the World“ and “The Future Is Faster Than You Think“. He has also worked with Tony Robbins to pen the powerful and transformative book, “Life Force”. His most recent project is “Exponential Organisations 2.0: The New Playbook for 10x Growth & Impact”, which Peter has co-authored with Salim Ismail and is a deep dive into how organisations can achieve exponential growth and impact by leveraging technology, innovation, and creativity. Peter believes the future belongs to those who can harness the power of exponential technologies and innovate at a very high pace, and those businesses that collaborate, embrace AI and all it brings will see huge success. As for the rest… well they'll get left behind. To underline just how significant the technological change that's coming is, and the unquantifiable impact it will have on our everyday lives, Peter explains that we'll experience more progress in the next decade up to 2033 than we've seen in the past century from 1923. Peter says the convergence of exponentially growing technologies, especially artificial intelligence, will reinvent every business model and accelerate the global pace of change. This is going to be a fascinating conversation and I can't wait to explore the ways Peter is looking to leverage AI and a whole host of metatrends that are going to shape the next decade. Peter is a really knowledgeable guy, incredibly successful, and fiercely passionate. He is also unwaveringly optimistic and cares deeply about the future of humanity and the planet. “We are witnessing a new breed of organisation that is scaling and generating value at a pace never before seen in business. It's important to understand why this is happening and how unprecedented this shift is.” Don't miss this one, especially if you want to learn about how our future world will look and more importantly how to prepare and profit from this technological revolution. Trailer Watch the trailer for this exclusive video interview with Peter Diamandis: Download clips A number of clips from this exclusive interview are now available to download, share and repost. Spread the word: grab these clips today! Is artificial general intelligence here already? Are we heading for a dystopian future? Are we prepared for artificial intelligence? AI renders the future harder to predict than ever before How to harness the power of change How to extend your lifespan 20-30 years Everything will have an AI-user interface A gateway to unprecedented potential and connection How to build a massive transformative purpose Using AI to build an exponential growth organization The Vatom NFT Platform takes extended reality to the next level We will see millions of humanoid robots Will AI end capitalism? What's it like to hang out with Elon Musk? What's next for Peter Diamandis?

Peter is the Founder & Executive Chairman of the XPRIZE Foundation and the Executive Founder of Singularity University. He has started over 25 companies in the areas of health-tech, space, venture capital and education. Among other roles, Peter is the Co-founder and Vice-Chairman of two public companies, Celularity and Vaxxinity. He is also the Co-founder & Chairman of Fountain Life, and the Co-founder of BOLD Capital Partners, a venture capital firm focused on longevity and other exponential technologies. Peter is a bestselling author of four books: Abundance, Bold, The Future is Faster Than You Think, and Life Force which he co-authored with Tony Robbins. He was named one of the “World's 50 Greatest Leaders" by Fortune. Follow Peter on Twitter @PeterDiamandis. [0:16] - How Peter became fascinated by the concept of age reversal [4:02] - Peter's transitioning of focus from space to longevity [10:26] - Making sacrifices to reach longevity escape velocity [18:58] - Why underpopulation is riskier than overpopulation [20:23] - Escaping the “pro-aging” trance [22:22] - Peter's take on the current state of longevity technology [26:20] - The history and purpose of Peter's XPRIZE competition [35:03] - Why Peter champions the development of positive mindsets [40:24] - How to turn a scarcity mindset into an abundance mindset [44:15] - Why you should define your Massive Transformative Purpose (MTP) [50:30] - How Peter manages to make progress across so many projects in parallel For more episodes, go to ⁠podofjake.com⁠. Previous guests include ⁠Mark Cuban⁠, ⁠Vitalik Buterin⁠, ⁠Brian Armstrong⁠, ⁠Balaji Srinivasan⁠, ⁠Keith⁠ ⁠Rabois⁠, ⁠Ali Spagnola⁠, ⁠Anthony Pompliano⁠, ⁠Raoul Pal⁠, ⁠Julia Galef⁠, ⁠Jack Butcher⁠, ⁠Tim Draper⁠, and over 100 others alike. Learn from founders and CEOs of companies like ⁠OpenAI⁠, ⁠Coinbase⁠, ⁠Solana⁠, ⁠Polygon⁠, ⁠AngelList⁠⁠, ⁠Oura⁠⁠, and ⁠Replit⁠, and investors from ⁠Founders⁠ ⁠Fund⁠, ⁠a16z⁠, ⁠Union Square Ventures⁠, and many more. I appreciate your support and hope you enjoy. Thanks to ⁠⁠Chase Devens⁠⁠ for the show notes and ⁠⁠Yiction⁠⁠ for the music. Lastly, I love hearing from fans of the pod. Feel free to email me any time at ⁠jake@blogofjake.com⁠. Thank you!

This episode is brought to you by Rupa Health, ButcherBox, Pendulum, and Apollo.I don't just want to live a long life, I want to feel good while I'm doing it. That's why I'm always interested in the latest therapies to slow the aging process. Stem cells are one of those therapies that have been gaining a lot of traction for reducing nerve and muscle pain, improving the appearance and health of hair and skin, and even increasing sexual vitality.Today on The Doctor's Farmacy, I'm excited to talk to Dr. Bob Hariri about stem cell therapy and how it's changing the field of aging science and the future of human health. Dr. Bob Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine, and aerospace. He is the chairperson, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases. He holds over 170 issued and pending patents for discoveries, including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts.This episode is brought to you by Rupa Health, ButcherBox, Pendulum, and Apollo.Rupa Health is a place where Functional Medicine practitioners can access more than 3,000 specialty lab tests from over 35 labs. You can check out a free, live demo with a Q&A or create an account at RupaHealth.com.Right now ButcherBox has a special offer: new members can get New York strip steaks for a year PLUS $20 off your first order at Butcherbox.com/farmacy with code FARMACY.Pendulum is offering my listeners 20% off their first month of an Akkermansia subscription with code HYMAN at Pendulumlife.com.Apollo was designed by neuroscientists and physicians to tap into your body's natural rhythms to bring calm and focus and restore equilibrium to your nervous system. You can check out the Apollo wearable and save $40 by visiting apolloneuro.com/drhyman.Here are more details from our interview (audio version / Apple Subscriber version):Three things people commonly do to shorten lifespan (6:07 / 3:40) Why stem cells are so remarkable (10:20 / 7:52) Retrieving and injecting stem cells into the body (15:07 / 12:40) Embryonic and placental stem cells (19:47 / 16:46) Capabilities of injected stem cells (28:14 / 24:12) Reprogramming your biology for a younger you (35:50 / 31:20) Cell therapies beyond stem cells (52:05 / 47:33) Natural killer cells (55:28 / 50:54) Tips for healthy aging (1:15:15 / 1:10) Learn more at celularity.com and check out pilotinghealth.com. Hosted on Acast. See acast.com/privacy for more information.

Today's Sponsors:http://betterhelp.com/impacttheoryAthletic Greens: Go to athleticgreens.com/impact and receive a FREE 1 year supply of Vitamin D AND 5 free travel packs with your first purchase! INVEST IN YOURSELF NOW: https://bit.ly/3htGayAFREE LIVE WORKSHOP HOW TO MAKE ANY GOAL STICK, REGISTER NOW: https://bit.ly/3htGayAOn Today's Episode: Not many people would turn down living a longer healthier life. More time to make an impact on the world, more time to enjoy the people you love, and more time to build your legacy, all seem like great reasons to live as long as possible in the healthiest state possible.Dr. Robert Hariri has dedicated the last 25+ years to treating life-threatening diseases and stands behind his work and technological advances in cellular therapy that make cellular therapy the obvious solution to nature's way of healing our bodies, but even better. Dr. Hariri co-authored the bestseller, Lifespan with Tony Robbins and Peter Diamandis and is a surgeon, biomedical scientist and entrepreneur. His contributions and knowledge in stem cell research and application that could change the health of the world are mind-blowing.In this episode take a look at three things you're doing daily that shorten your lifespan, and discover all the ways better health and longevity are being reimagined that could happen in our lifetime.SHOW NOTES:0:00 | Introduction to Dr. Bob Hariri0:10 | This Is Shortening Your Lifespan10:36 | Cellular Function 10121:47 | Traumatic Brain Injury Inflammation31:31 | Debunking Stem Cell Myths44:12 | Path to Stem Cell Approval52:39 | Stem Cells Are Nature's First Aid1:09:03 | Power of Placental Stem Cells 1:21:36 | Reverse Aging with Cellular Therapy1:31:41 | Build Muscle to Age BetterQUOTES:“There's no doubt everything associated with the health, wellness, repairability, and recoverability in our body is driven by the immune system.” [23:29]“We are on the threshold of cellular medicine becoming the most logical, the most deployable, the most impactful way of treating disease because it's the way nature treats disease, [...] stem cells are nature's first aid kit.” [55:04]“Natural selection will always upregulate the trait that gives you a survival advantage.” [1:07:16]“We're providing an alternative to nature's attempt to close these defects by supporting it with a supplement, and the supplement is in the form of a structural material and or the cells.” [1:19:51]“If you maintain your muscle mass and strength into your advanced years, [...] you have a lower risk of dying from cancer by 30-40%.” [1:34:28]“One of the best things you can you do in response to injury or illness is exercise.” [1:35:28]“Active muscle actually helps your immune function and helps initiate the process of repair and recovery.” [1:38:31]Follow Dr. Bob Hariri:Website: https://celularity.com/ Twitter: https://twitter.com/celularity Facebook: https://www.facebook.com/celularity Instagram: https://www.instagram.com/celularity/ YouTube: https://www.youtube.com/channel/UCosHfzZER3Y8UZ93Rem59sQ

Recently named by Fortune as one of the “World's 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is co-founder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company, co-founder of Fountain Life, an innovative, fully-integrated platform delivering best-in-class predictive, preventative, personalized and data-driven health, and co-founder & Vice Chairman of COVAXX, a COVID-19 antibody and vaccine company. Diamandis is a New York Times Bestselling author of three books: Abundance – The Future Is Better Than You Think, BOLD – How to Go Big, Create Wealth & Impact the World and The Future is Faster Than You Think.

Mei Mei Hu: Mei Mei is also CEO of United Neuroscience and a member of the executive committee of United Biomedical, Inc. She oversaw the launch of one of the first endobody vaccines in the world and the successful spin-out of three companies. Mei Mei was formerly a consultant at McKinsey & Company where she advised pharmaceutical companies on strategic, operational and organizational issues. Prior to that, Mei Mei was in the Securities group at Cravath, Swaine and Moore. Mei Mei is also co-founder of an investment and advisory group with active investments in real estate, energy and life sciences. She was named to Time 100 Next list, Fortune 40 under 40, and Young Global Leaders of World Economic Forum. She holds a B.A. from University of Pennsylvania and her J.D. from Harvard Law School. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. Peter Diamandis: As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released in 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”

A chance to listen again to one of our most inspiring podcasts of 2020. Captured during Visioneering at Paramount Studios, Peter H. Diamandis is joined by Harrison Ford and Wes Bush from Conservation International. In a thrilling discussion, they discuss the urgency to change the economics, behaviors and political will in order to save the planet. It requires the support of everyone, and will rely on technological innovation and new economic incentives to move in the right direction, quickly. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Harrison Ford has become one of the most popular and acclaimed actors of our time. His works include 35 feature films, ten of which have exceeded $100 million each at the box office. Through his starring roles in such cinematic blockbusters as the Star Wars and Indiana Jones trilogies, The Fugitive, Air Force One, Patriot Games and K-19 he has come to embody the quintessential hero for moviegoers around the world. Strongly committed to environmental concerns, Harrison Ford has served on the board of Conservation International for more than 10 years, actively participating in its design and growth. During this time CI has emerged as a leading force in global conservation. He presently serves as vice chair of the board and is on CI's Executive Committee.He has played an instrumental role in the establishment at CI of the Center for Applied Biodiversity Science, the first early warning system for global conservation efforts. Additionally, he played a key role in the design and development of CI's Center for Environmental Leadership in Business, a coalition of conservation and business interests searching for ways to reduce the impact of development on the earth's biodiversity. Mr. Ford serves as a board member of Conservation International's Global Conservation Fund, which has secured the protection of over 40,000,000 acres on 3 continents in the past 18 months. Mr. Ford lives in Jackson, Wyoming, where he donated 389 acres of his property for a conservation easement to the Jackson Hole Land Trust.Prior to becoming CEO of Northrop Grumman, Wes Bush held numerous leadership roles at Northrop Grumman including President and Chief Operating Officer; Corporate Vice President and Chief Financial Officer; and President of the Space Technology division. He joined the company as a systems engineer at TRW in 1987 and was the President and CEO of TRW’s Aeronautical Systems business when Northrop Grumman acquired the TRW in 2002. He earlier worked at Aerospace Corporation and Comsat Labs. Bush received both a bachelor’s degree and a master’s degree in electrical engineering from the Massachusetts Institute of Technology. He is also a graduate of the Executive Management Program at UCLA. He serves on the board of directors of Conservation International and the U.S. Naval Academy Foundation, and he chairs the boards of the Aerospace Industries Association and the Business-Higher Education Forum.Links: https://www.conservation.org/https://xprize.org/blog See acast.com/privacy for privacy and opt-out information.

For over 25 years, XPRIZE has convened the brightest minds from around the globe to tackle the world’s greatest challenges. One of the most pressing problems facing humanity today is food insecurity, and the need for nutritious, affordable, and sustainably-sourced food has reached critical status. In this exciting episode hosted by XPRIZE Founder and Executive Chairman, Peter H. Diamandis, we’re talking to world-renowned author, philanthropist and business strategist, Tony Robbins, as he discusses the inspiration behind the latest competition, $15M XPRIZE Feed the Next Billion.By 2050, Earth’s population will have reached 9.7 billion. The demand for high protein products is increasing while the impact from current meat production practices is devastating our planet. The COVID-19 pandemic has worsened food insecurity, food safety, and access for many communities around the world. Furthermore, cities projected to face rapid population growth and wealth increase are experiencing surges in demand for poultry and fish as opposed to red meat. While there is increasing activity in utilizing plant-based and cultivated approaches to create meat alternatives, more work is needed to make it widespread. XPRIZE Feed the Next Billion is a $15M competition incentivizing teams to produce chicken and fish alternatives that replicate or outperform conventional protein in structure, versatility, sensory properties, and nutritional profile, while having a lower comparable environmental footprint.Today’s guest, Tony Robbins, is an entrepreneur, #1 NY Times best-selling author, philanthropist, and the nation’s #1 life and business strategist. Author of six internationally bestselling books, including the recent New York Times #1 best-seller MONEY: Master the Game and UNSHAKEABLE, Mr. Robbins has empowered more than 50 million people from 100 countries through his audio, video and life training programs. He created the #1 personal and professional development program of all time, and more than 4 million people have attended his live seminars.Tony Robbins has made it one of his life's missions to help feed as many people as possible. As a philanthropist, through his partnership with Feeding America, Mr. Robbins has provided over 500 million meals in the last 5 years to those in need. He is on track to provide 1 billion meals over the next 5 years. He has also initiated programs in more than 1,500 schools, 700 prisons, and 50,000 service organizations and shelters. He provides fresh water to 250,000 people a day in India in order to fight waterborne diseases, the number one killer of children in that country. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Links:XPRIZE.org See acast.com/privacy for privacy and opt-out information.

For over 25 years, XPRIZE has convened the brightest minds from around the globe to tackle the world’s greatest challenges. One of the most pressing problems facing humanity today is food insecurity, and the need for nutritious, affordable, and sustainably-sourced food has reached critical status. In this exciting episode with XPRIZE Founder and Executive Chairman, Peter H. Diamandis, Tony talks about the inspiration behind the latest competition, $15M XPRIZE Feed the Next Billion. By 2050, Earth’s population will have reached 9.7 billion. The demand for high protein products is increasing while the impact from current meat production practices is devastating our planet. The COVID-19 pandemic has worsened food insecurity, food safety, and access for many communities around the world. Furthermore, cities projected to face rapid population growth and wealth increase are experiencing surges in demand for poultry and fish as opposed to red meat. While there is increasing activity in utilizing plant-based and cultivated approaches to create meat alternatives, more work is needed to make it widespread. XPRIZE Feed the Next Billion is a $15M competition incentivizing teams to produce chicken and fish alternatives that replicate or outperform conventional protein in structure, versatility, sensory properties, and nutritional profile, while having a lower comparable environmental footprint. Tony has made it one of his life's missions to help feed as many people as possible. His family struggled to put food on the table growing up, and it was one stranger’s kindness that inspired Tony to give back as an adult. As a philanthropist, through his partnership with Feeding America, Tony has provided over 500 million meals in the last 5 years to those in need. He’s on track to provide 1 billion meals over the next 5 years. He has also initiated programs in more than 1,500 schools, 700 prisons, and 50,000 service organizations and shelters.  He provides fresh water to 250,000 people a day in India in order to fight waterborne diseases, the number one killer of children in that country.  Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.” These two men have so much to offer our planet. Solving world hunger while saving the environment? It’s the stuff of miracles, thanks to Tony and Peter and the brilliant minds of these competitors.   

At the inaugural Business Leaders Roundtable Discussion, we talked with Dr. Robert Hariri about: 1. His research into Natural Killer Cells to fight COVID-19 2. Where we are in the war against the virus 3. The strides Celularity is making toward increasing human longevity This event has been organized by Frank D'Souza and James Barrood. Dr. Hariri is an accomplished surgeon, biomedical scientist, and serial entrepreneur in two technology sectors, biomedicine and aerospace. He is the chairman, founder, and chief executive officer of Celularity, Inc., one of the world's leading human cellular therapeutics companies. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc. Dr. Hariri has served on numerous public boards including Cryoport (NASDAQ:CYRX). Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration. He is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). Dr. Hariri and his team of scientists were the first to obtain FDA approval to use its cryopreserved allogeneic, off-the-shelf Natural Killer (NK) cell therapy to treat COVID-19 infected adults. He holds over 170 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. He has authored over 150 published chapters, articles, and abstracts. Dr. Hariri was the recipient of the Pontifical Medal for Innovation awarded by Pope Francis in 2018 for his discovery of placental stem cells and advances in immunotherapy and regenerative medicine. Dr. Hariri twice received the Thomas Alva Edison Award for invention, in 2007 and 2011, and is a recipient of the Children's Brain Tumor Foundation's Fred J. Epstein Lifetime Achievement Award. Dr. Hariri was recipient of the Genius of New Jersey Award in 2019 and over the years has received numerous other honors for his many contributions to the fields of biomedicine and aviation. Dr. Hariri is an Adjunct Professor of Neurosurgery and member of the Board of Overseers of the Weill Cornell Medical College and a former member of the board of visitors of the Columbia University School of Engineering and Applied Sciences, and the Science & Technology Council of the College of Physicians and Surgeons. He is a member of the X PRIZE Foundation scientific advisory board for the Archon X PRIZE for Genomics. Dr. Hariri is a trustee and vice-chair of the Liberty Science Center. In 2010 he was appointed a Commissioner of Cancer Research by New Jersey Governor Chris Christie.

If ever a biotech unwittingly begged for FDA scrutiny by virtue of its business model, it was Celularity. The company is working on a host of biologic therapies, the development of which is dependent on the large-scale collection of stem cells harvested from afterbirth in maternity wards across the globe. That's an approach that simply begs for FDA oversight, which is why Celularity founder Dr. Robert Hariri makes for an excellent discussion on the importance of data quality and complete master files for FDA submissions.

In this episode, our podcast host Dr. Emily Church looks at how technology is innovating modern medicine at an exponential rate to be smarter and proactive. In a special recording from Visioneering, XPRIZE founder Peter H. Diamandis is joined by two of the world’s greatest entrepreneurs: iBOT & Segway inventor engineer Dean Kamen, and science innovator and founder of United Therapeutics, Martine Rothblatt. They discuss the future of health and medicine where biology IS technology. Drawing from their own inspirational experience, including printing new organs, and eradicating diabetes and Alzheimers, Peter, Dean and Martine discuss the positive impact that innovation is having on human health and longevity. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Dr. Martine Rothblatt founded Lung Biotechnology, as well as its parent company, United Therapeutics, in order to develop therapies for orphan diseases such as PAH. She earned her PhD in medical ethics from the Royal London School of Medicine and Dentistry, Queen Mary College, University of London and also obtained JD and MBA degrees from the University of California at Los Angeles. Prior to entering the life sciences field, Dr. Rothblatt was active in satellite communications, founding Sirius XM Satellite Radio and serving as its Chairman and CEO. She has also published many books, including Your Life or Mine: How Geoethics Can Resolve the Conflict Between Public and Private Interests in Xenotransplantation.Dean Kamen, Founder of FIRST and President of DEKA Research & Development CorporationDean Kamen is an inventor, an entrepreneur, and a tireless advocate for science and technology. His roles as inventor and advocate are intertwined—his own passion for technology and its practical uses has driven his personal determination to spread the word about technology's virtues and by so doing to change the culture of the United States.As an inventor, he holds more than 440 U.S. and foreign patents, many of them for innovative medical devices that have expanded the frontiers of health care worldwide. While still a college undergraduate, he invented the first wearable infusion pump, which rapidly gained acceptance from such diverse medical specialties as oncology, neonatology, and endocrinology. In 1976, he founded his first medical device company, AutoSyringe, Inc., to manufacture and market the pumps. Then, working with leading diabetes researchers, Dean pioneered the design and adoption of the first portable insulin pump. It was quickly demonstrated that using a pump could much more effectively control patients’ blood glucose levels. . At age 30, he sold AutoSyringe to Baxter Healthcare Corporation. Following the sale of AutoSyringe, Inc., he founded DEKA Research & Development Corporation to develop internally generated inventions as well as to provide research and development for major corporate clients. Kamen led DEKA's development of the HomeChoiceTM peritoneal dialysis system for Baxter International Inc. The HomeChoiceTM system allows patients to be dialyzed in the privacy and comfort of their home and quickly became the worldwide market leader. Kamen also led the development of technology to improve slide preparation for the CYTYC (now Hologic Inc.) ThinPrep® Pap Test. Kamen-led DEKA teams have also developed critical components of the UVARTM XTSTM System, an extracorporeal photophereisis device marketed by Therakos, a unit of Johnson & Johnson, for treatment of T-Cell lymphoma. An advanced prosthetic arm in development for DARPA should advance the quality of life for returning injured soldiers. Other notable developments include the HydroflexTM surgical irrigation pump for C.R. Bard, the CrownTM stent, an improvement to the original Palmaz-Schatz stent, for Johnson & Johnson, the iBOTTM mobility device, and the Segway® Human Transporter.Kamen has received many awards for his efforts. Notably, Kamen was awarded the National Medal of Technology in 2000. Presented by President Clinton, this award was in recognition for inventions that have advanced medical care worldwide, and for innovative and imaginative leadership in awakening America to the excitement of science and technology. Kamen was elected a member of the National Academy of Engineering in 1997. He was awarded the Lemelson-MIT Prize in 2002, and was inducted into the National Inventors Hall of Fame in May 2005. He is a Fellow of the American Institute for Medical & Biological Engineering, as well as many other national and international engineering organizations.In 2010, Dean hosted the Planet Green television series Dean of Invention.In addition to DEKA, one of Dean's proudest accomplishments is founding FIRST® (For Inspiration and Recognition of Science and Technology), an organization dedicated to motivating the next generation to understand, use and enjoy science and technology. Founded in 1989, this year FIRST® will serve more than 1,000,000 young people, ages 6 to 18, in more than 86 countries around the globe. Last year, high-school-aged participants were eligible to apply for more than $50 million in scholarships from over 200 leading colleges, universities, and corporations.Links: https://www.firstinspires.org/robotics/frchttps://www.unither.com/ See acast.com/privacy for privacy and opt-out information.

In this episode, XPRIZE founder Peter H. Diamandis discusses AI and how it is often portrayed in science fiction with world renowned sci-fi author Kim Stanley Robinson, at XPRIZE Visioneering recorded at Paramount Studios. Robinson questions our relationship with AI and the important future of synthetic medicine. Although he is inspired by space exploration, he argues that the race to Mars is not an urgent problem, but rather a reward for fixing the problems on planet Earth. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Kim Stanley Robinson is an American novelist, widely recognized as one of the foremost living writers of science fiction. Robinson began publishing novels in 1984. His work has been described as "humanist science fiction" and "literary science fiction". Robinson himself has been a proud defender and advocate of science fiction as a genre, which he regards as one of the most powerful of all literary forms.Robinson was born in Waukegan, Illinois, but moved to Orange County, California, when he was two. As a child he loved to play in the orange groves stretching out for miles around his home, so when suburban sprawl began to encroach and the groves were torn out and paved over, the rapid change of modern life hit close to home. It was not until college in 1971 that he would stumble upon new wave science fiction and find in it an expression of that very sense of rapid change that had made such an impression upon him growing up, at which point he knew almost immediately that he would be committed to science fiction from then on. He enrolled at the University of California-San Diego (UCSD) in 1970 and received his B.A. in Literature in 1974. During that time he developed the idea to write a trio of books exploring three different alternative future histories in which southern California had gone down different paths, what became the Orange County trilogy. After briefly leaving California to receive an M.A. in English at Boston University in 1975, Robinson returned to UCSD to complete his Ph.D. Though science fiction was something of a "literary ghetto culture" in the academic world, Robinson could not have had a more sympathetic advisor in Fredric Jameson, who suggested that Robinson do his thesis on the works of Philip K. Dick, whom Robinson was not particularly familiar with at the time but whom Jameson regarded as the greatest living American novelist. Robinson agreed to the idea and finished his Ph.D. in 1982, a revised version of which was published in 1984 as The Novels Of Philip K. Dick. In 1978 Robinson took a break from his Ph.D. work and moved north to Davis, California, where he worked in a bookstore and spent a lot of time outdoors, especially backpacking in the mountains, where he continued to develop his love for landscape and the outdoors. While in Davis he met Lisa Howland Nowell, an environmental chemist, and in 1982 upon completing his Ph.D. he returned to Davis and the two were married. He taught freshman composition among other courses at UC Davis, another autobiographical tidbit that would be bestowed upon his fictional alter-ego Jim in 1988's The Gold Coast. Then a few years later, after publishing his first few novels, his wife's post-doctoral work in environmental toxicology took the couple to Switzerland, where they lived for two years, and at which point he began to write full time. Her work also took them to Washington, D.C., and during their four years there Robinson was a stay-at-home parent to their first son while his wife worked. Finally, in 1991 they moved back to Davis to buy a house in Village Homes -- a planned community that shares many things in common with the community depicted in his 1990 novel Pacific Edge -- where their second son was born. Robinson is still the stay-at-home parent, giving him plenty of time to write, while his wife continues to work full time as a chemist. As a result, much of the couple's social circle is made up of her friends and colleagues, giving Robinson ample material with which to write about scientists. As can be gathered from above, Robinson enjoys inserting personal life experiences or autobiographical elements in his works. For example:Robinson enjoys mountaineering greatly, which can be seen in landscape descriptions and trekking trips in nearly all his works.His stay in Switzerland is a likely inspiration for frequent references to Swiss government and people (Green Mars, Fifty Degrees Below).He has visited Greece and enjoys the architecture of the Greek islands (The Gold Coast, Blue Mars).He likes softball, referenced in Icehenge and Pacific Edge, and plays the frisbee golf described in Fifty Degrees Below.At times he is a stay-at-home dad, like Charlie Quibler in the Science In The Capital trilogy.He is a Californian teacher, like characters in The Gold Coast and The Years Of Rice And Salt.Links: https://www.kimstanleyrobinson.info See acast.com/privacy for privacy and opt-out information.

The Stock Day Podcast welcomed SANUWAVE Health, Inc. (SNWV)(“the Company”), a shockwave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. CEO of the Company, Kevin Richardson, joined Stock Day host Everett Jolly.  READ FULL PRESS RELEASE: https://stockdaymedia.com/sanuwave-health-inc-discusses-the-potential-of-their-celularity-acquisition-with-the-stock-day-podcast-snwv-july-1-2020/

Episode 2: In this episode, join XPRIZE founder and Star Trek superfan, Peter H. Diamandis for a special recording at Visioneering with LeVar Burton, Marina Sirtis and Rod Roddenberry from Star Trek: The Next Generation live from Paramount Studios. XPRIZE’s vision of a future of abundance is inspired by Star Trek’s IDIC (Infinite Diversity Infinite Combinations) and this incredible line-up discusses their inspiration from the franchise including female empowerment, living in a post-scarcity world and how Star Trek’s technology predictions are starting to come true. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”LeVar Burton is an American actor, director, producer, and author. Burton first came to prominence portraying Kunta Kinte in the 1977 award-winning ABC television miniseries Roots, based on the novel by Alex Haley. He is also well known for his role as Lt. Commander Geordi La Forge in Star Trek: The Next Generation as well as the host of the PBS children's program Reading Rainbow.Marina Sirtis is a British-American actress. She is best known for her role as Counselor Deanna Troi on the television series Star Trek: The Next Generation and the four feature films that followed, as well as other appearances in the Star Trek franchise.Rod Roddenberry Rod Roddenberry is a producer, CEO of Roddenberry Entertainment, and son of Gene Roddenberry, screenwriter, producer and creator of the original Star Trek television series, and its first spin-off The Next Generation. Links: Levarburton.com roddenberry.com/https://www.diamandis.com/ See acast.com/privacy for privacy and opt-out information.

NEW SEASONWelcome to Future Positive from XPRIZE. This season we aim to bring you the most future-forward topics, covering everything from AI to avatars, to climate change, and more. We will share conversations from game-changing leaders, tech entrepreneurs and heavyweights from the creative industry - revealing their inspirations, and how and why they will change the world.Captured during Visioneering at Paramount Studios, Peter H. Diamandis is joined by Harrison Ford and Wes Bush from Conservation International. In a thrilling discussion, they discuss the urgency to change the economics, behaviors and political will in order to save the planet. It requires the support of everyone, and will rely on technological innovation and new economic incentives to move in the right direction, quickly. Recently named by Fortune as one of the “World’s 50 Greatest Leaders,” Peter H. Diamandis is the founder and executive chairman of the XPRIZE Foundation, which leads the world in designing and operating large-scale incentive competitions. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is cofounder of BOLD Capital Partners, a venture fund with $250M investing in exponential technologies, and co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. Diamandis is a New York Times Bestselling author of two books: Abundance – The Future Is Better Than You Think and BOLD – How to go Big, Create Wealth & Impact the World. His newest book in this series of exponential technologies—The Future is Faster Than You Think—was released on January 28, 2020. He earned degrees in molecular genetics and aerospace engineering from the MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “the best way to predict the future is to create it yourself.”Harrison Ford has become one of the most popular and acclaimed actors of our time. His works include 35 feature films, ten of which have exceeded $100 million each at the box office. Through his starring roles in such cinematic blockbusters as the Star Wars and Indiana Jones trilogies, The Fugitive, Air Force One, Patriot Games and K-19 he has come to embody the quintessential hero for moviegoers around the world. Strongly committed to environmental concerns, Harrison Ford has served on the board of Conservation International for more than 10 years, actively participating in its design and growth. During this time CI has emerged as a leading force in global conservation. He presently serves as vice chair of the board and is on CI's Executive Committee.He has played an instrumental role in the establishment at CI of the Center for Applied Biodiversity Science, the first early warning system for global conservation efforts. Additionally, he played a key role in the design and development of CI's Center for Environmental Leadership in Business, a coalition of conservation and business interests searching for ways to reduce the impact of development on the earth's biodiversity. Mr. Ford serves as a board member of Conservation International's Global Conservation Fund, which has secured the protection of over 40,000,000 acres on 3 continents in the past 18 months. Mr. Ford lives in Jackson, Wyoming, where he donated 389 acres of his property for a conservation easement to the Jackson Hole Land Trust.Prior to becoming CEO of Northrop Grumman, Wes Bush held numerous leadership roles at Northrop Grumman including President and Chief Operating Officer; Corporate Vice President and Chief Financial Officer; and President of the Space Technology division. He joined the company as a systems engineer at TRW in 1987 and was the President and CEO of TRW’s Aeronautical Systems business when Northrop Grumman acquired the TRW in 2002. He earlier worked at Aerospace Corporation and Comsat Labs. Bush received both a bachelor’s degree and a master’s degree in electrical engineering from the Massachusetts Institute of Technology. He is also a graduate of the Executive Management Program at UCLA. He serves on the board of directors of Conservation International and the U.S. Naval Academy Foundation, and he chairs the boards of the Aerospace Industries Association and the Business-Higher Education Forum.Links: https://www.conservation.org/https://xprize.org/blog See acast.com/privacy for privacy and opt-out information.

In this episode of Going Green, Dylan Welch talks with the CEO of Celularity, Robert Hariri, M.D., Ph.D. Robert has done amazing things in his life, from being in the military, to being a surgeon, to being a movie producer, to building Cellularity, Dr. Hariri is a perfect example of someone who is Going Green.www.GoingGreenShow.comwww.DylanWelch.comwww.GreenWatches.orgwww.celularity.comSupport the show (http://www.GoingGreenShow.com)

Ira Pastor, ideaXme life sciences ambassador and founder of Bioquark, interviews Dr. Robert Hariri, MD, PhD, surgeon, bio-medical scientist and highly successful serial entrepreneur in two technology sectors: bio-medicine and aerospace. Dr. Hariri Utilizes Biomedicine to Aid Human Longevity Dr. Hariri is Chairman, Founder, and CEO, of Celularity, Inc., a clinical-stage cell therapeutics company developing allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immuno-therapy and functional regeneration, which recently got initial clearance from the U.S. Food and Drug Administration (FDA) to begin early-stage clinical trials on a potential treatment for Covid-19. Dr. Hariri is also Co-Founder and Vice Chairman, of Human Longevity, Inc., a company merging extensive amounts of human genotype and phenotype data with machine learning, so that it can help develop new ways to fight diseases associated with aging. Dr. Hariri served as Chairman, Founder, Chief Scientific Officer, and Chief Executive Officer of Celgene Cellular Therapeutics (acquired by Bristol Myers Squibb), one of the world’s largest human cellular therapeutics companies, where he pioneered the use of stem cells to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering. Recognition, Awards and Accolades Dr. Hariri is a graduate of Columbia College and Columbia University School of Engineering and Applied Sciences and earned his MD and PhD degrees from Cornell University Medical College. He trained in surgery at the New York Hospital-Cornell Medical Center, where he also directed the Aitken Neurosurgery Laboratory and the Center for Trauma Research. Dr. Hariri has over 90 issued and pending patents, has authored over 100 published chapters, articles and abstracts, and is most recognized for his discovery of pluripotent stem cells from placenta, and as a member of the team which discovered the physiological activities of tumor necrosis factor (TNF). Dr. Hariri was recipient of the Thomas Alva Edison Award in 2007 and 2011, The Fred J. Epstein Lifetime Achievement Award and has received numerous other honors for his many contributions to bio-medicine and aviation. Dr. Hariri also serves on numerous Boards of Directors. Dr. Hariri is an Adjunct Associate Professor of Pathology at the Mount Sinai School of Medicine, a member of the Board of Visitors of the Columbia University School of Engineering & Applied Sciences, and the Science & Technology Council of the College of Physicians and Surgeons, and is a member of the scientific advisory board for the Archon X PRIZE for Genomics, which is awarded by the X PRIZE Foundation. Dr. Hariri is also a Trustee of the Liberty Science Center and has been appointed Commissioner of Cancer Research by NJ Governor Christie. Dr. Hariri is also a member of the Board of Trustees of the J. Craig Venter Institute. A jet-rated commercial pilot with thousands of hours of flight time in over 60 different military and civilian aircraft, Dr. Hariri has also produced several feature films as well as documentaries on global societal issues. On this ideaXme episode we will hear from Dr. Hariri about: His background, how he developed an interest in medicine, in surgery, and in the field of stem cells and aging. About the intuition early on in his career that placenta was one of those overlooked and untapped biological resources – not just in terms of stem cells but in the unique cocktails of secreted factors that were capable of immunomodulation and controlling cancer metastasis. About Celularity's initial clearance from the Food and Drug Administration to begin early-stage clinical trials on a potential treatment for Covid-19 using “Natural Killer” (NK) cell therapies to boost the immune system’s disease-fighting response. About his interests in the "Myokinome" - the fact that skeletal muscle is an endocrine organ capable of secreting proteins termed 'myokines', which participate in tissue cross-talk, providing a critical link in the exercise–health paradigm. About his work at Human Longevity Inc. About his work with the XPRIZE Foundation and views on early stage biotechnology funding in 2020. About his work in the aerospace field with groups including the asteroid mining company, Planetary Resources and the Rocket Racing League. This interview is in American English Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter: @IraSamuelPastor If you liked this interview, be sure to interview with Prof. Collin Ewald! Follow ideaXme on Twitter: @ideaxm On Instagram: @ideaxme On YouTube: ideaxme Find ideaXme across the internet including on iTunes, SoundCloud, Radio Public, TuneIn Radio, I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.  

Medical supply chains that transport medications for chronically ill patients are at risk of shutting down due to COVID-19. And for those that have contracted the disease, getting access to clinical trials is not an easy process. For at-risk patients, accessing life-saving medications is becoming increasingly more difficult. This week on the Patients Rising Podcast, we discuss treatment testing for coronavirus. We also discuss how the strain on the medical supply chain is impacting the routine medications relied on by thousands of chronically ill Americans. Finally, we follow up with some good patient news on Michael Goldsmith’s acceptance into a coronavirus clinical trial. Robert Hariri, M.D, Ph.DChairman, Founder, and CEO of CelularityDr. Robert Hariri is an experienced surgeon and biomedical scientist. His research focuses on utilizing stem cells for the treatment of numerous human diseases, particularly in the areas of immuno-oncology and cell therapy. Dr. Hariri’s major medical discoveries include his findings on human placenta-derived stem cells, which include pluripotent stem cells and novel immune cells. For nearly 14 years, Dr. Hariri served as the CEO of Celgene’s Cellular Therapeutics division, a global pharmaceutical company. In 2014, he co-founded Human Longevity, Inc., a genomics-based biotechnology company. Currently, Dr. Hariri serves as Chairman and CEO of Celularity. The biotech company focuses on cell therapy research based on Dr. Hariri’s findings on the uses of postpartum placenta cells. This research guides Celularity’s work in immuno-oncology and hematology. Dr. Hariri earned his B.A. in Biological Anthropology from Columbia University and his M.D. and Ph.D. from Cornell University. Hosts:Terry Wilcox, Executive Director, Patients RisingDr. Robert Goldberg, “Dr. Bob”, Co-Founder and Vice President of the Center for Medicine in the Public Interest.Kate Pecora, Field Correspondent Links:Fight Like a WarriorPatients Rising Concierge Need help?The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands. Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.orgHave a question or comment about the show, want to suggest a show topic or share your story as a patient correspondent?Drop us a line: podcast@patientsrising.org The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.

I had the privilege and honor to host 77 WABC's radio show to discuss everything Americans need to know about the historic $2 trillion stimulus package and the recent French hydroxychloroquine study that shows efficacy. We are joined by two distinguished guests, Charlie Kirk, Founder of Turning Point USA and Dr. Robert Hariri, CEO of Celularity! Thank you for your support! Don't forget to comment below with your Common Sense & don’t forget to subscribe to my podcast at https://www.RudyGiulianiCS.com► Connect with Rudy Giuliani on Twitter: https://www.twitter.com/RudyGiuliani► Connect with Rudy Giuliani on Instagram: https://www.instagram.com/therudygiuliani► Connect Rudy Giuliani on Facebook: https://www.facebook.com/realrudygiuliani

In this episode of Common Sense, we are joined by a very prominent guest in the medical field, Dr. Robert (Bob) Hariri, MD, Ph.D., the Founder, Chairman and CEO of Celularity.Thank you for your support & don’t forget to subscribe to my podcast at https://www.RudyGiulianiCS.com► Connect with Rudy Giuliani on Twitter: https://www.twitter.com/RudyGiuliani► Connect with Rudy Giuliani on Instagram: https://www.instagram.com/therudygiuliani► Connect Rudy Giuliani on Facebook: https://www.facebook.com/realrudygiuliani

Today we'll discuss longevity and the future, along with a little reminiscing, with serial entrepreneur and visionary, Dr. Peter Diamandis. He is a NY Times Best Selling Author and his latest book is The Future is Faster Than You Think. Peter is  the founder and executive chairman of the XPRIZE Foundation and executive founder of Singularity University. As an entrepreneur, Diamandis has started over 20 companies in the areas of longevity, space, venture capital and education. He is co-founder of venture fund, BOLD Capital Partners, co-founder and Vice Chairman of Celularity, Inc., a cellular therapeutics company. 

Today: A look at Scientific Research to battle Covid19. Lots of great work at numerous sites. I focus on fascinating research by a company called Celularity trying to harness the body's natural killer cells to fight for those most vulnerable. How these NK cells are collected and preserved is fascinating and it is quite possible this could be a solution now---and in the future.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D. talks with Mark Alyn about the revolution in cellular medicine.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D.​ talks with Mark Alyn about the revolution in cellular medicine.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D. talks with Mark Alyn about the revolution in cellular medicine.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D. talks with Mark Alyn about the revolution in cellular medicine.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D.​ talks with Mark Alyn about the revolution in cellular medicine.

At Celularity, our vision is to be a world-leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases. Robert Hariri, MD, Ph.D. talks with Mark Alyn about the revolution in cellular medicine.

This episode of Bulletproof Radio is recorded in person at the XPRIZE event (which Bulletproof is sponsoring) with the neurosurgeon, Dr. Bob Hariri.Dr. Hariri is an amazing human being with 30 years of experience as a neurosurgeon and a medical entrepreneur. He has created a huge number of startups that have been innovating at the very forefront of how we can gain control of our own biology.Dr. Hariri's work has now expanded to include anti-ageing, longevity and stem cell treatments particularly with a company called Celularity which is pioneering some of the most innovative ways we can live longer than we ever thought we could.

This episode of Bulletproof Radio is recorded in person at the XPRIZE event (which Bulletproof is sponsoring) with the neurosurgeon, Dr. Bob Hariri.Dr. Hariri is an amazing human being with 30 years of experience as a neurosurgeon and a medical entrepreneur. He has created a huge number of startups that have been innovating at the very forefront of how we can gain control of our own biology.Dr. Hariri's work has now expanded to include anti-ageing, longevity and stem cell treatments particularly with a company called Celularity which is pioneering some of the most innovative ways we can live longer than we ever thought we could.

The billionaires of the world want to live forever. They have invested billions to develop treatments that will grant them immortality. What if they succeed? What if they already succeeded in the past? What if there were previous earth civilizations where their "billionaires" achieved immortality and launched breakaway civilizations only to return to the earth as "gods."I believe this has happened and is happening again. Jeff Bezos, Peter Thiel, Larry Ellison and many other billionaires are spending hundreds of millions of dollars in search of the fountain of youth. When they succeed, they will be the leaders of the next wave of billionaire "Watchers" who breakaway from civilization and live in space. When these new gods return, they will take their place next to the last generation of immortals like Zeus and Osiris and help man re-boot civilization. What to contribute to the action? Follow us on Facebook athttps://www.facebook.com/hebeheberadio/If you find the shows interesting, please give us a LIKE and subscribe.

The billionaires of the world want to live forever. They have invested billions to develop treatments that will grant them immortality. What if they succeed? What if they already succeeded in the past? What if there were previous earth civilizations where their "billionaires" achieved immortality and launched breakaway civilizations only to return to the earth as "gods."I believe this has happened and is happening again. Jeff Bezos, Peter Thiel, Larry Ellison and many other billionaires are spending hundreds of millions of dollars in search of the fountain of youth. When they succeed, they will be the leaders of the next wave of billionaire "Watchers" who breakaway from civilization and live in space. When these new gods return, they will take their place next to the last generation of immortals like Zeus and Osiris and help man re-boot civilization. What to contribute to the action? Follow us on Facebook athttps://www.facebook.com/hebeheberadio/If you find the shows interesting, please give us a LIKE and subscribe.

Dr. Bob Hariri is an accomplished Air Force pilot, neurosurgeon, biomedical scientist, and self-made billionaire entrepreneur. But he still has more to do. His work with stem cells is helping treat life-threatening diseases to improve human longevity with new company Celularity. Bob talks about dedicating his life to improving the lives of others on this episode of Impact Theory with Tom Bilyeu. The Impact Theory Podcast is sponsored by Health IQ, an insurance company that helps health-conscious people like runners, cyclist, weightlifters and vegetarians get lower rates on their life insurance. Go to healthiq.com/Impact to support the show and see if you qualify!  SHOW NOTES: Bob explains how and why he is still so driven. [3:40] Bob describes what the future of medicine looks like. [11:00] Tom and Bob discuss problem-solving and growth in business. [21:06] Bob shares what traits have contributed the most to his success. [29:50] Bob reveals the impact he wants to have on the world. [34:25]   QUOTES: “We know that we have the ability to change the world. We know that we've already taken steps in that direction. If we don't follow it to the end game, people like you and me will wind up feeling totally unfulfilled and frustrated.” [5:18]   “You have to surround yourself with people who approach things differently, who challenge you, not a lot of sycophants who just want to make you happy.” [22:52]   “Only do something you absolutely love. Don't do anything because you're doing it for me or for your mom or for your friends or for the rest of your family. You're doing it because this is where you want to spend your time.” [33:25]   FOLLOW BOB HARIRI: TWITTER: http://bit.ly/2CkTLCI LINKEDIN: http://bit.ly/2FwGUvT   MENTIONED IN THIS EPISODE   BOOKS: Einstein’s Dreams - http://amzn.to/2GLKgut [13:53] Extreme Ownership - http://amzn.to/2F7QWFK [25:25] Principles - http://amzn.to/2F94Wzh [27:56]   PEOPLE: Peter Diamandis - http://bit.ly/2r9XYCO [0:45]   COMPANIES: Human Longevity - http://bit.ly/2oy2xUy [1:20] Celgene - http://bit.ly/2sURgTv [1:25] Celularity - http://bit.ly/2wCkk3s [2:40]   CONCEPTS: Pluripotent Stem Cells - http://on.bchil.org/2EScUxi [2:04]   EVENTS: Abundance 360 - http://bit.ly/2Dx303n [0:44]